Buserelin-depot lyophilizate for susp. / m prolong. 320.93mg 3.75mg vial with a solvent amp.2ml with a syringe, needle, swab

$85.92

Buserelin-depot lyophilizate for susp. / m prolong. 320.93mg 3.75mg vial with a solvent amp.2ml with a syringe, needle, swab

Quantity:

SKU: 1524984318 Categories: , Tags: ,

Description

Composition
Active substance:
1 vial contains: 3.75 mg of buserelin acetate in the form of free peptide 1 ampoule of solvent contains: D-Mannitol 16 mg Water for injections 2 ml.
Excipients:
DL copolymer of lactic and glycolic acids 200 mg, D-Mannitol 85 mg Sodium carboxymethyl cellulose 30 mg polysorbate 80 2 mg.
Description:
Lyophilized powder or white with a slight yellowish color.
Solvent-colorless transparent liquid.
Product form:
Bottle lyophilisate in blister together with the solvent in the vial (2 ml), and two disposable syringe needle and instructions for use placed in a cardboard box.
Contraindications
Pregnancy, lactation, hypersensitivity to the drug.
Dosage
3.75 mg
Indications
Hormone-dependent prostate cancer,
Mammary cancer,
Endometriosis (pre- and postoperative periods)
uterine fibroids,
Endometrial hyperplasia,
Infertility treatment (during the in vitro fertilization program (IVF).
Interaction with other drugs
Simultaneous application Buserelin preparation with preparations containing hormones (e.g., in an ovulation induction regime) can contribute to ovarian hyperstimulation syndrome.
With simultaneous use may reduce the effectiveness Buserelin hypoglycemic agents.
Overdose
Currently, the cases of drug overdose Buserelin were reported.
pharmachologic effect
Pharmacological group:
The antitumor agent, a gonadotropin-releasing hormone (GnRH) analogue.
Pharmacodynamics:
A synthetic analogue of the natural gonadotropin-releasing hormone (GnRH). Buserelin competitively binds to the cell receptors of the anterior pituitary, causing a short-term increase in the level of sex hormones in the blood plasma. Further application of therapeutic doses of the drug results (an average of 12-14 days) to complete blockade gonadotropic pituitary function, inhibiting, thus selection luteinizing (LH) and follicle stimulating hormone (FSH). As a result of the suppression of the synthesis of sex hormones in the gonads, which is manifested decrease of estradiol concentration in blood plasma values ​​to post-menopausal women and a reduction of testosterone to postcastration levels in men.
testosterone concentration during continuous treatment for 2-3 weeks is reduced to a content characteristic of the state of orchiectomy, i.e. called pharmacological castration.
Pharmacokinetics:
Bioavailability is high. Maximum plasma concentration is reached approximately 2-3 hours after intramuscular injection and is retained at a level sufficient to inhibit the synthesis of gonadotrophins by the pituitary gland of at least 4 weeks.
Conditions of supply of pharmacies
By prescription.
side effects
Allergic reactions: urticaria, flushing of the skin, rarely – angioedema.
The women – the typical side effects are a manifestation of the state of progress gipoestrogennnogo – “pharmacological menopause”:
CNS: frequent changes of mood, sleep disturbances, depression, headache.
From the side of endocrine status, “tides”, increased sweating, vaginal dryness, decreased libido, abdominal pain, bone demineralization, seldom – menstrualnopodobnoe bleeding (usually in the first few weeks of treatment).
In men with prostate cancer treatment – during the first 2-3 weeks after the first injection and can exacerbate the progression of the underlying disease, which is associated with the stimulation of the synthesis of gonadotrophins and consequently testosterone, gynecomastia, transient increase in androgen concentrations in the blood (rare – ossalgiya , urinary retention, renal edema, muscle weakness in the lower extremities, lymphostasis).
Other: in single cases (causal relationship has not been clearly established) – pulmonary embolism, diarrheal disorders.
special instructions
Among women
Patients with any form of depression during treatment with Buserelin should be under close medical supervision.
Ovulation induction should be under strict medical supervision. In the initial stage of treatment may develop ovarian cysts. Prior to the beginning of treatment is recommended to exclude pregnancy and to stop taking hormonal contraceptives, but during the first two months of the drug is necessary to use other (non-hormonal) method of contraception.
men
In order to effectively prevent possible side effects in the first phase of action of the drug is necessary to use anti-androgens for two weeks prior to the first injection buserelin – depot and for two weeks after the first injection.
Effects on ability to drive and use other mechanisms
Caution should be exercised when administering the drug to patients involved in potentially hazardous activities that require attention and speed of mental and motor responses.
Storage conditions
Store in the dark and away from children at a temperature of 8 ° to 25 ° C.
Dosing and Administration
In hormone-prostate cancer: 3.75 mg intramuscular (i / m) every 4 weeks;
In the treatment of endometriosis, endometrial hyperplasia: 3.75 mg / m once every 4 weeks. Treatment starts in the first five days of the menstrual cycle. Duration of treatment – 4-6 months .;
In the treatment of uterine fibroids: 3.75 mg / m once every 4 weeks. Treatment starts in the first five days of the menstrual cycle. Duration of treatment – 3 months prior to surgery, in other cases – 6 months;
In the treatment of infertility by in vitro fertilization (IVF): 3.75 mg / m once on day 2 of the menstrual cycle.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg
Manufacturer

FARM-SYNTHESIS

There are no reviews yet.

Add your review